Revenue
2020
2021
2022
2023
2024
2025
CASI Pharmaceuticals, Inc. (CASIF)
Price$0.1530Cached quote
Net income
2020
2021
2022
2023
2024
2025
Free cash flow
2020
2021
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | |
|---|---|---|---|---|---|---|
| Revenue | $20.7M | $28.5M | $33.9M | $38.0M | $30.0M | $15.0M |
| Gross profit | $10.1M | $11.1M | $20.1M | $27.3M | $17.6M | $5.6M |
| Gross margin | 48.65% | 39.06% | 59.19% | 71.70% | 58.66% | 37.55% |
| Research & development | $6.3M | $8.9M | $9.9M | $16.0M | $14.4M | $11.5M |
| Operating expenses | $55.1M | $50.8M | $45.1M | $61.3M | $59.1M | $58.4M |
| Operating income | −$45.0M | −$39.6M | −$25.1M | −$34.0M | −$41.5M | −$52.8M |
| Operating margin | −217.30% | −138.84% | −74.03% | −89.45% | −138.29% | −351.85% |
| EBITDA | −$43.8M | −$38.3M | −$22.6M | −$32.8M | −$41.0M | −$52.2M |
| EBITDA margin | −211.51% | −134.29% | −66.65% | −86.29% | −136.63% | −347.85% |
| Net income | −$48.1M | −$39.3M | −$27.0M | −$41.0M | −$36.7M | −$48.3M |
| Net profit margin | −232.03% | −137.57% | −79.58% | −107.80% | −122.10% | −321.89% |
| Basic EPSper basic share | -$2.59 | -$2.56 | -$2.02 | -$3.01 | -$2.69 | -$4.37 |
| Diluted EPSper diluted share | -$2.59 | -$2.56 | -$2.02 | -$3.01 | -$2.69 | -$4.37 |
Owners
Reported shareholders
Reported holdings Number of shares
View holders
| Holder | Shares held |
|---|---|
Huang James | 4.53M |
He Wei-Wu | 3.75M |
Wu Alex | 34.17K |
WEST PACES ADVISORS INC. | 100 |
Bars compare reported share counts. A matching total for this share class and reporting period is unavailable, so percentages are not shown.
Source: SEC Form 3 ↗Updated Sep 29, 2026 · Quarterly data